Ignite Creation Date:
2025-12-25 @ 12:22 AM
Ignite Modification Date:
2026-01-11 @ 6:29 AM
Study NCT ID:
NCT00624858
Status:
COMPLETED
Last Update Posted:
2012-10-30
First Post:
2008-02-19
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003863', 'term': 'Depression'}, {'id': 'D003244', 'term': 'Consciousness Disorders'}, {'id': 'D050177', 'term': 'Overweight'}, {'id': 'D009765', 'term': 'Obesity'}], 'ancestors': [{'id': 'D001526', 'term': 'Behavioral Symptoms'}, {'id': 'D001519', 'term': 'Behavior'}, {'id': 'D019954', 'term': 'Neurobehavioral Manifestations'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D019965', 'term': 'Neurocognitive Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}, {'id': 'D044343', 'term': 'Overnutrition'}, {'id': 'D009748', 'term': 'Nutrition Disorders'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D001835', 'term': 'Body Weight'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 25}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2008-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2012-10', 'dispFirstSubmitDate': '2012-10-23', 'completionDateStruct': {'date': '2009-07', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2012-10-23', 'studyFirstSubmitDate': '2008-02-19', 'dispFirstSubmitQcDate': '2012-10-23', 'studyFirstSubmitQcDate': '2008-02-26', 'dispFirstPostDateStruct': {'date': '2012-10-30', 'type': 'ESTIMATED'}, 'lastUpdatePostDateStruct': {'date': '2012-10-30', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2008-02-27', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2009-07', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'To assess the change in depressive symptoms as measured by Montgomery-Asberg Depression Rating Scale (MADRS) total score at 12 weeks', 'timeFrame': '12 Weeks'}], 'secondaryOutcomes': [{'measure': 'To assess the percentage change from baseline in total body weight at 12 and 24 weeks.', 'timeFrame': '12 and 24 weeks'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Depression', 'depressed', 'overweight', 'obese'], 'conditions': ['Depression']}, 'referencesModule': {'references': [{'pmid': '24171147', 'type': 'DERIVED', 'citation': 'McElroy SL, Guerdjikova AI, Kim DD, Burns C, Harris-Collazo R, Landbloom R, Dunayevich E. Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study. Prim Care Companion CNS Disord. 2013;15(3):PCC.12m01494. doi: 10.4088/PCC.12m01494. Epub 2013 Jun 20.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in the treatment of major depression in overweight or obese subjects.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Female and male subjects must be 18 to 65 years of age;\n* Have body mass index (BMI) greater or equal to 27 and less than or to equal 43kg/m2;\n* Meet criteria for major depression\n* Women of child-bearing potential, must be non-lactating and agree to use effective contraception throughout the study period and 30 days after discontinuation of study drug;\n* Able to comply with all required study procedures and schedule;\n* Able to speak and read English;\n* Willing and able to give written informed consent\n\nExclusion Criteria:\n\n* Obesity of known endocrine origin\n* Serious medical condition\n* History of drug or alcohol abuse or dependence\n* Use of excluded concomitant medications\n* History of surgical or device (e.g. gastric banding) intervention for obesity;\n* History or predisposition to seizures\n* Pregnant or breast-feeding women or planning to become pregnant during the study period or within 30 days of discontinuing study drug;\n* Planned surgical procedure that can impact the conduct of the study;\n* Use of investigational drug, device or procedure within 30 days prior to Screening;\n* Participation in any previous clinical trial conducted by Orexigen Therapeutics;\n* Any condition which in the opinion of the investigator makes the subject unsuitable for inclusion in the study.'}, 'identificationModule': {'nctId': 'NCT00624858', 'briefTitle': 'A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression', 'organization': {'class': 'INDUSTRY', 'fullName': 'Orexigen Therapeutics, Inc'}, 'officialTitle': 'An Open-Label Study Assessing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) in Overweight or Obese Subjects With Major Depression', 'orgStudyIdInfo': {'id': 'NB-402'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'NB32', 'description': 'Naltrexone SR 32 mg/Bupropion SR 360 mg/ day', 'interventionNames': ['Drug: naltrexone SR 32 mg/ bupropion SR 360 mg daily']}], 'interventions': [{'name': 'naltrexone SR 32 mg/ bupropion SR 360 mg daily', 'type': 'DRUG', 'description': 'All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.\n\nDuring the study, subjects will receive ancillary therapy including advice on diet and exercise', 'armGroupLabels': ['NB32']}]}, 'contactsLocationsModule': {'locations': [{'zip': '45040', 'city': 'Mason', 'state': 'Ohio', 'country': 'United States', 'facility': 'Lindner Center of HOPE', 'geoPoint': {'lat': 39.36006, 'lon': -84.30994}}], 'overallOfficials': [{'name': 'Susan McElroy, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Cincinnati'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Orexigen Therapeutics, Inc', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}